Revolution Medicines (RVMD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Revolution Medicines (RVMD)
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Key Insights
Critical company metrics and information
Share Price
$48.25Market Cap
$8.12 BillionTotal Outstanding Shares
168.22 Million SharesTotal Employees
490Dividend
No dividendIPO Date
February 13, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.revmed.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-541.89 Million |
| Net Cash Flow From Operating Activities, Continuing | $-539.71 Million |
| Net Cash Flow From Financing Activities | $924.96 Million |
| Net Cash Flow, Continuing | $-156.64 Million |
| Net Cash Flow From Investing Activities, Continuing | $-541.89 Million |
| Net Cash Flow | $-156.64 Million |
| Net Cash Flow From Operating Activities | $-539.71 Million |
| Net Cash Flow From Financing Activities, Continuing | $924.96 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Earnings Per Share | $3.66 |
| Revenues | $742000.00 |
| Diluted Earnings Per Share | $3.66 |
| Income/Loss From Continuing Operations Before Tax | $-566.72 Million |
| Operating Expenses | $653.94 Million |
| Net Income/Loss Attributable To Parent | $-567.06 Million |
| Income Tax Expense/Benefit | $343000.00 |
| Basic Average Shares | $341.23 Million |
| Diluted Average Shares | $341.23 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Income/Loss From Continuing Operations After Tax | $-567.06 Million |
| Other Operating Expenses | $95.75 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Operating Income/Loss | $-653.20 Million |
| Net Income/Loss | $-567.06 Million |
| Research and Development | $553.19 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Nonoperating Income/Loss | $86.48 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-567.06 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity | $1.57 Billion |
| Assets | $1.76 Billion |
| Intangible Assets | $56.94 Million |
| Other Current Liabilities | $86.41 Million |
| Accounts Payable | $24.46 Million |
| Noncurrent Liabilities | $85.83 Million |
| Equity Attributable To Parent | $1.57 Billion |
| Current Liabilities | $110.86 Million |
| Current Assets | $1.58 Billion |
| Liabilities | $196.69 Million |
| Other Non-current Assets | $102.11 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Liabilities And Equity | $1.76 Billion |
| Noncurrent Assets | $183.86 Million |
| Fixed Assets | $24.81 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.